tbuckley/cabot-search huggingface dataset:
Efficacy of screening mammography. A meta-analysis
Authors: K. Kerlikowske
Journal: JAMA (1995)

<h3>Objective.</h3> —To determine the efficacy of screening mammography by age, number of mammographic views per screen, screening interval, and duration of follow-up. <h3>Design.</h3> —Literature review and meta-analysis. <h3>Data Identification and Analysis.</h3> —Literature search of English-language studies reported from January 1966 to October 31, 1993, using MEDLINE, manual literature review, and consultation with experts. A total of 13 studies were selected, and their results were combined using meta-analytic techniques based on the assumption of fixed effects. <h3>Main Results.</h3> —The overall summary relative risk (RR) estimate for breast cancer mortality for women aged 50 to 74 years undergoing screening mammography compared with those who did not was 0.74 (95% confidence interval [CI], 0.66 to 0.83). The magnitude of the benefit in this age group was similar regardless of number of mammographic views per screen, screening interval, or duration of follow-up. In contrast, none of the summary RR estimates for women aged 40 to 49 years was significantly less than 1.0, irrespective of screening intervention or duration of follow-up. The overall summary RR estimate in women aged 40 to 49 years was 0.93 (95% CI, 0.76 to 1.13); the summary RR estimate for those studies that used two-view mammography was 0.87 (95% CI, 0.68 to 1.12) compared with 1.02 (95% CI, 0.73 to 1.44) for those studies that used one-view mammography, and for those studies with 7 to 9 years of follow-up, the summary RR estimate was 1.02 (95% CI, 0.82 to 1.27) compared with 0.83 (95% CI, 0.65 to 1.06) for those studies with 10 to 12 years of follow-up. <h3>Conclusion.</h3> —Screening mammography significantly reduces breast cancer mortality in women aged 50 to 74 years after 7 to 9 years of follow-up, regardless of screening interval or number of mammographic views per screen. There is no reduction in breast cancer mortality in women aged 40 to 49 years after 7 to 9 years of follow-up. Screening mammography may be effective in reducing breast cancer mortality in women aged 40 to 49 years after 10 to 12 years of follow-up, but the same benefit could probably be achieved by beginning screening at menopause or 50 years of age. (<i>JAMA</i>. 1995;273:149-154)
Long term results of non cultured epidermal cellular grafting in vitiligo, halo nevi, piebaldism and nevus depigmentosus
Authors: N. Van Geel, E. Wallaeys, B.K. Goh, M. De Mil, J. Lambert
Journal: British Journal of Dermatology (2010)

Journal Article Long‐term results of noncultured epidermal cellular grafting in vitiligo, halo naevi, piebaldism and naevus depigmentosus Get access N. Van Geel, N. Van Geel Department of Dermatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium Correspondence: Nanja van Geel. E‐mail: Nanja.vangeel@UGent.be Search for other works by this author on: Oxford Academic Google Scholar E. Wallaeys, E. Wallaeys Department of Dermatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium Search for other works by this author on: Oxford Academic Google Scholar B.K. Goh, B.K. Goh Pigment Clinic, National Skin Center, 1 Mandalay Road, Singapore 308205 Search for other works by this author on: Oxford Academic Google Scholar M. De Mil, M. De Mil Department of Dermatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium Search for other works by this author on: Oxford Academic Google Scholar J. Lambert J. Lambert Department of Dermatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 163, Issue 6, 1 December 2010, Pages 1186–1193, https://doi.org/10.1111/j.1365-2133.2010.10014.x Published: 01 December 2010
Interaction of mature CD3+CD4+ T cells with dendritic cells triggers the development of tertiary lymphoid structures in the thyroid
Authors: T. Marinkovic
Journal: Journal of Clinical Investigation (2006)

Ectopic expression of CC chemokine ligand 21 (CCL21) in the thyroid leads to development of lymphoid structures that resemble those observed in Hashimoto thyroiditis. Deletion of the inhibitor of differentiation 2 (Id2) gene, essential for generation of CD3–CD4+ lymphoid tissue–inducer (LTi) cells and development of secondary lymphoid organs, did not affect formation of tertiary lymphoid structures. Rather, mature CD3+CD4+ T cells were critical for the development of tertiary lymphoid structures. The initial stages of this process involved interaction of CD3+CD4+ T cells with DCs, the appearance of peripheral-node addressin–positive (PNAd+) vessels, and production of chemokines that recruit lymphocytes and DCs. These findings indicate that the formation of tertiary lymphoid structures does not require Id2-dependent conventional LTis but depends on a program initiated by mature CD3+CD4+ T cells.
From the Agency for Health Care Policy and Research
Authors: J. Jarrett Clinton
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LG-26GERMLINE AND SOMATIC FGFR1 ABNORMALITIES IN DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMORS
Authors: Barbara Rivera, Tenzin Gayden, Jian Carrot-Zhang, Javad Nadaf, Talia Boshari, Damien Faury, Michele Zeinieh, Romeo Blanc, David Burk, Somayyeh Fahiminiya, Eric Bareke, Ulrich Schüller, Camelia M. Monoranu, Ronald Sträter, Kornelius Kerl, Thomas Niederstadt, Gerhard Kurlemann, Benjamin Ellezam, Zuzanna Michalak, Maria Thom, Paul Lockhart, Richard Leventer, Milou Ohm, Duncan MacGregor, David Jones, Jason Karamchandani, Celia M.T. Greenwood, Albert Berghuis, Susanne Bens, Reiner Siebert, Magdalena Zakrzewska, Pawel P. Liberski, Krzysztof Zakrzewski, Sanjay Sisodiya, Werner Paulus, Steffen Albrecht, Martin Hasselblatt, Nada Jabado, William D. Foulkes, Jacek Majewski
Journal: Neuro-Oncology (2016)
Life expectancy with atrial septal defect. Influence of complicating pulmonary vascular disease
Authors: J. E. Dalen
Journal: JAMA (1967)

Of 48 patients with secundum atrial septal defects diagnosed by cardiac catheterization from 1945 to 1956, 29 (60%) were still alive in 1966. Survival was markedly influenced by the presence of complicating pulmonary vascular disease. Twenty-one of 23 patients with normal pulmonary vascular resistance were still alive in 1966. However, only five of 20 patients with pulmonary vascular disease were alive (average age, 50). Six of these 20 patients died at surgery, and nine of their heart disease (average age, 41). Catheterization during the follow-up period showed that severe pulmonary vascular disease had developed in two patients. The impossibility of predicting in which patients severe pulmonary vascular disease will develop, combined with the prohibitive surgical risk that it presents, suggests that all atrial defects without pulmonary vascular disease should be surgically corrected.
DIABETES AS A MANIFOLD DISEASE.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SPONTANEOUS RECOVERY IN MESENTERIC VASCULAR OCCLUSION
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TEMPERATURE AND BASAL METABOLISM
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Predictors of Clinical Response of Non–Small Cell Cancer to Gefitinib—Reply
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
H. Pylori and Gastric Cancer
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article H. Pylori and Gastric Cancer Get access JNCI: Journal of the National Cancer Institute, Volume 83, Issue 23, 4 December 1991, Page 1701, https://doi.org/10.1093/jnci/83.23.1701 Published: 04 December 1991
Contents
Authors: R Moreau, R Bataller, T Berg, S Lotersztajn, J Zucman-Rossi, R Jalan, F Averhoff, J Lazarus, D Sergeenko, M Colombo, A Gamkrelidze, T Tsertsvadze, M Butsashvili, D Metreveli, L Sharvadze, M Hellard, S Gnes, T Gabunia, M Nasrullah, P Kwo, J Heimbach, S Shetty, J Boyer, S Borgia, J Dearden, E Yoshida, S Shafran, A Brown, Z Ben-Ari, M Cramp, C Cooper, M Foxton, C Rodriguez, R Esteban, R Hyland, S Lu, B Kirby, A Meng, S Markova, H Dvory-Sobol, A Osinusi, R Bruck, J Ampuero, S Ryder, K Agarwal, R Fox, D Shaw, S Haider, B Willems, Y Lurie, J Calleja, E Gane, J Llaneras, M Riveiro-Barciela, S Lens, M Diago, A Cachero, J Garcı ´a-Samaniego, I Conde, A Arencibia, J Arenas, F Gea, X Torras, J Luis Calleja, J Carrio, I Ferna ´ndez, R Marı ´a Morillas, J Rosales, I Carmona, C Ferna ´ndez-Rodrı ´guez, M Herna ´ndez-Guerra, S Llerena, V Bernal, J Turnes, J Gonza ´lez-Santiago, S Montoliu, B Figueruela, E Badia, M Delgado, M Ferna ´ndez-Bermejo, M In ˜arrairaegui, J Pascasio, Z Marin, M Buti, C Soon, P Behrendt, D Todt, M Manns, H Wedemeyer, M Sa ¨llberg Chen, M Cornberg, S Yang, L Wang, W Pan, W Bayer, C Thoens, K Heim, U Dittmer, J Timm, Q Wang, Q Yu, J Luo, Y Liu, M Hofmann, R Thimme, X Zhang, H Chen, H Wang, X Feng, X Yang, Y Lu, M Lu, D Yang, J Liu, J Dillon, M Miller, E Robinson, A Hapca, M Rezaeihemami, C Weatherburn, P Mcintyre, B Bartlett, P Donnan, K Boyd, E Dow, T Lu, C Zhang, J Xu, Z Xue, R Busuttil, N Xu, Q Xia, J Kupiec-Weglinski, H Ji, X Wang, Q He, H Shen, A Xia, W Tian, W Yu, B Sun, J Wang, M Peters, N Ding, S Ribback, K Utpatel, A Cigliano, F Dombrowski, M Xu, X Chen, X Song, L Che, M Evert, A Cossu, J Gordan, Y Zeng, D Calvisi, G Zhou, D Sprengers, S Mancham, R Erkens, P Boor, A Van Beek, M Doukas, L Noordam, L Campos Carrascosa, V De Ruiter, R Van Leeuwen, W Polak, J De Jonge, B Koerkamp, B Van Rosmalen, T Van Gulik, J Verheij, J Ijzermans, M Bruno, J Kwekkeboom
Journal: Journal of Hepatology (2019)
Abstract 4904: High levels of microRNA-210-3p are associated with increased risk of disease progression in breast cancer patients treated with docetaxel
Authors: BARBARA PASCULLI, RAFFAELA BARBANO, MICHELINA RENDINA, ANDREA FONTANA, MASSIMILIANO COPETTI, VANNA MARIA VALORI, MARIA MORRITTI, EVARISTO MAIELLO, VITO MICHELE FAZIO, MANEL ESTELLER, PAOLA PARRELLA
Journal: Cancer Research (2019)

Abstract MiR-210-3p is the most hypoxia-sensitive miRNA showing overexpression in different human cancers, but its role as biomarker in breast cancer (BC) is still controversial. In our study, we performed the expression analysis of miR-210-3p in a retrospective cohort of breast cancer patients with a median follow-up of 91 months enrolled according to the REMARK guidelines (n=284). As controls, 13 normal breast tissues (NBTs) from reductive mammoplasty were also profiled. By this analysis, we found that miR-210-3p levels were significantly increased in tumours as compared with NBTs (P=0.021). According to the surrogate molecular classification, the Triple Negative subgroup showed the highest levels of miR-210, followed by Luminal B tumours, whereas Luminal A, and HER2-amplified tumours showed the lowest expression levels (P=0.0137). The evaluation of the association of miR-210-3p with time-to-event outcomes in patients without synchronous metastases (n=268) demonstrated an association between risk of disease progression (HR 2.13, 95%CI 0.33-3.39, P=0.002) and higher levels of miR-210-3p in the subgroup treated with docetaxel in sequential therapy with anthracyclines (ECD). Moreover, a cut-off value of 20.966 as established by ROC curve analysis allowed to discriminate patients who developed distant metastases with an accuracy of 85% at 3-years (AUC 0.87, CI 0.69-1) and 83% at 5-years follow up (AUC 0.832, CI 0.656-1). Instead, the accuracy in discriminating patients who died for the disease was of 79.6% at both 5- (AUC 0.804, CI 0.517-1) and 10-years (AUC 0.804 CI 0.517-1) follow up. Overall, our data support the putative involvement of miR-210-3p in the response to treatments including docetaxel and suggest its eligibility to become a biomarker of early metastases development in ECD-treated breast cancer patients. Citation Format: BARBARA PASCULLI, RAFFAELA BARBANO, MICHELINA RENDINA, ANDREA FONTANA, MASSIMILIANO COPETTI, VANNA MARIA VALORI, MARIA MORRITTI, EVARISTO MAIELLO, VITO MICHELE FAZIO, MANEL ESTELLER, PAOLA PARRELLA. High levels of microRNA-210-3p are associated with increased risk of disease progression in breast cancer patients treated with docetaxel [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4904.
THE COCAIN HABIT.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Molecular Films: The Cyclotron &amp;amp; The New Biology
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Peer Review and Dissenting Manuscripts: The Cantekin Case
Authors: William F. Donaldson
Journal: JAMA (1990)

<h3>To the Editor.—</h3> We are writing with respect to the report entitled "Biomedical Information, Peer Review, and Conflict of Interest as They Influence Public Health,"<sup>1</sup>which appeared in your March 9 issue. The authors of that report (a bioengineer, an economist, and a lawyer) present their version of "an actual case" in which they (and we) have been involved. Central to virtually every point Dr Cantekin and his coauthors attempt to make is their portrayal of Dr Cantekin's 1986 submission to the<i>New England Journal of Medicine</i>as a "dissenting manuscript" concerning the Otitis Media Research Center's Antibiotic for Otitis Media With Effusion—I (AB-OME-I) clinical trial. That portrayal is misleading and erroneous. The manuscript submitted by Dr Cantekin et al to the<i>New England Journal of Medicine</i>(Cantekin et al) was not written as a dissent to the Otitis Media Research Center's report of results of the AB-OME-I trial,
ANNUAL REPORT ON INTERNSHIPS AND RESIDENCIES
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal